Stephanie A. Toll

Stephanie A. Toll

Auto-generated profile, based on publicly available information

Stephanie A. Toll

Children’s Hospital of Michigan, Central Michigan University School of Medicine, Saginaw, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
JFJawad Fares
Jawad Fares
ZDZachary B. Davis
Zachary B. Davis
JRJulian Simon Rechberger
Julian Simon Rechberger
STStephanie A. Toll
Stephanie A. Toll
JSJonathan D. Schwartz
Jonathan D. Schwartz
SKSoumen Khatua
Soumen Khatua
Despite advances in treatment regimens that comprise surgery, chemotherapy, and radiation, outcome of many brain tumors remains dismal, more so when they recur. The proximity of brain tumors to delicate neural structures often precludes complete surgical resection. Toxicity and long-term side effects of systemic therapy remain a concern. Novel therapies are warranted. The field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. This provides a new avenue for the treatment of cancerous lesions in the brain. In this review, we explore the mechanisms by which the brain tumor microenvironment suppresses NK cell mediated tumor control, and the methods being used to create NK cell products that subvert immune suppression. We discuss the pre-clinical studies evaluating NK cell-based immunotherapies that target several neuro-malignancies and highlight advances in molecular imaging of NK cells that allow monitoring of NK cell-based therapeutics. We review current and ongoing NK cell based clinical trials in neuro-oncology.

14 October 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
MAMurat AK
Murat AK
STS.A. Toll
S.A. Toll
KHK.Z. Hein
K.Z. Hein
RCR.R. Colen
R.R. Colen
SKSoumen Khatua
Soumen Khatua
SUMMARY: Exponential technologic advancements in imaging, high-performance computing, and artificial intelligence, in addition to increasing access to vast amounts of diverse data, have revolutionized the role of imaging in medicine. Radiomics is defined as a high-throughput feature-extraction method that unlocks microscale quantitative data hidden within standard-of-care medical imaging. Radiogenomics is defined as the linkage between imaging and genomics information. Multiple radiomics and radiogenomics studies performed on conventional and advanced neuro-oncology image modalities show that they have the potential to differentiate pseudoprogression from true progression, classify tumor subgroups, and predict recurrence, survival, and mutation status with high accuracy. In this article, we outline the technical steps involved in radiomics and radiogenomics analyses with the use of artificial intelligence methods and review current applications in adult and pediatric neuro-oncology.

18 July 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
JRJulian Simon Rechberger
Julian Simon Rechberger
STStephanie A. Toll
Stephanie A. Toll
WVWouter Jan François Vanbilloen
Wouter Jan François Vanbilloen
DDDavid J Daniels
David J Daniels
SKSoumen Khatua
Soumen Khatua
Medulloblastoma is the most common malignant brain tumor in children. Over the last few decades, significant progress has been made in revealing the key molecular underpinnings of this disease, leading to the identification of distinct molecular subgroups with different clinical outcomes. In this review, we provide an update on the molecular landscape of medulloblastoma and treatment strategies. We discuss the four main molecular subgroups (WNT-activated, SHH-activated, and non-WNT/non-SHH groups 3 and 4), highlighting the key genetic alterations and signaling pathways associated with each entity. Furthermore, we explore the emerging role of epigenetic regulation in medulloblastoma and the mechanism of resistance to therapy. We also delve into the latest developments in targeted therapies and immunotherapies. Continuing collaborative efforts are needed to further unravel the complex molecular mechanisms and profile optimal treatment for this devastating disease.

27 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JRJulian Simon Rechberger
Julian Simon Rechberger
STStephanie A. Toll
Stephanie A. Toll
SBSubhasree Biswas
Subhasree Biswas
HYHyo Bin You
Hyo Bin You
WCWilliam David Chow
William David Chow
SKSoumen Khatua
Soumen Khatua
Central nervous system (CNS) tumors are the leading cause of cancer-related mortality in children, with prognosis remaining dismal for some of these malignancies. Though the past two decades have seen advancements in surgery, radiation, and targeted therapy, major unresolved hurdles continue to undermine the therapeutic efficacy. These include challenges in suboptimal drug delivery through the blood–brain barrier (BBB), marked intra-tumoral molecular heterogeneity, and the elusive tumor microenvironment. Drug repurposing or re-tasking FDA-approved drugs with evidence of penetration into the CNS, using newer methods of intracranial drug delivery facilitating optimal drug exposure, has been an area of intense research. This could be a valuable tool, as most of these agents have already gone through the lengthy process of drug development and the evaluation of safety risks and the optimal pharmacokinetic profile. They can now be used and tested in clinics with an accelerated and different approach. Conclusions: The next-generation therapeutic strategy should prioritize repurposing oncologic and non-oncologic drugs that have been used for other indication, and have demonstrated robust preclinical activity against pediatric brain tumors. In combination with novel drug delivery techniques, these drugs could hold significant therapeutic promise in pediatric neurooncology.

18 September 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
STStephanie A. Toll
Stephanie A. Toll
MJMarjorie T. Jones
Marjorie T. Jones
EYEmi J. Yoshida
Emi J. Yoshida
GDGirish Dhall
Girish Dhall
AOArthur J. Olch
Arthur J. Olch
KWKenneth K. Wong
Kenneth K. Wong

1 December 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
STStephanie Toll
Stephanie Toll
AGAvanti Gupte
Avanti Gupte
SSSandeep Sood
Sandeep Sood
WKWilliam Kupsky
William Kupsky
DADeniz Altinok
Deniz Altinok
KBKanta Bhambhani
Kanta Bhambhani
DICER1 syndrome is a rare inherited tumor predisposition syndrome linked to an increased risk of several malignancies. Affected individuals most commonly develop pleuropulmonary blastoma (PPB) and ovarian sex cord-stromal tumors. Brain tumors in these patients are rare, however; the increased frequency of pineoblastoma in this population has been established. Traditionally, pineal parenchymal tumors of intermediate differentiation (PPTIDs) have not been associated with DICER1 syndrome, with research suggesting alternative mutations driving tumorigenesis. These tumors are pathologically and clinically diverse, with long-term surveillance based on therapeutic interventions. Here we describe a case of a germline DICER1 mutation in a patient with a PPTID, suggesting that this mutation is not limited to pineoblastoma as previously reported. CASE: We describe a 19 year-old female with a WHO grade III PPTID treated with multimodal therapy including surgery, craniospinal irradiation (CSI) and chemotherapy. She was noted to have a thyroid mass at diagnosis and was subsequently diagnosed with a benign thyroid nodule, followed most recently by a cataract with pathology concerning for medulloepithelioma of the ciliary body. Due to the known association between medulloepithelioma and DICER1 syndrome, targeted germline sequencing was obtained and confirmed a pathogenic heterozygous mutation. To our knowledge this is the first report of a PPTID in a patient with DICER1 syndrome. This association highlights the clinical implications of molecular evaluation in pediatric brain tumors, for both immediate therapeutic decisions and long-term surveillance.